title: Impact of ibuprofen therapy in the outcome of experimental pneumococcal acute otitis media treated with amoxicillin or erythromycin.
abstract: The impact of ibuprofen combined with amoxicillin or erythromycin for therapy of penicillin-resistant pneumococcal acute otitis media (AOM) was evaluated in a gerbil model. Ibuprofen (at 2.5 or 7.5 mg/kg, orally) and/or amoxicillin or erythromycin (5 mg/kg each, s.c.) were administered at 5 h (early therapy, as single-dose regimen) or at 18 h (delayed therapy, five doses) postinoculation (PI). Each antibiotic alone and combined with ibuprofen was more effective administered as early regimen than as delayed treatment when evaluating the presence of otorrhea, otoscopic aspect, culture-positive and bacterial counts in middle ear (ME) samples, and loss of body weight. There was a trend for a better bacteriological outcome in animals receiving amoxicillin or erythromycin and ibuprofen, especially with the high dose. Such a dose of ibuprofen, associated with each antibiotic regimen, also preserved the animal well-being, avoiding a great weight loss in comparison to those receiving the antibiotic alone but a statistically significant difference was only observed for animals receiving delayed therapy with erythromycin and high-dose ibuprofen. In conclusion, ibuprofen combined with antibiotics seemed to improve the outcome of this experimental pneumococcal AOM.
authors.affiliation: Unit for Research in Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz-Capio, 28040 Madrid, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: del Prado
authors.forename: Carmina
authors.initials: C
authors.lastname: Martínez-Marín
authors.forename: Lorena
authors.initials: L
authors.lastname: Huelves
authors.forename: Matilde
authors.initials: M
authors.lastname: Gracia
authors.forename: Violeta
authors.initials: V
authors.lastname: Rodríguez-Cerrato
authors.forename: Ricardo
authors.initials: R
authors.lastname: Fernández-Roblas
authors.forename: Carmen
authors.initials: C
authors.lastname: Ponte
authors.forename: Carlos
authors.initials: C
authors.lastname: Cenjor
authors.forename: Francisco
authors.initials: F
authors.lastname: Soriano
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002648:Child; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D005849:Gerbillinae; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology*; D011008:Pneumococcal Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004917:Erythromycin; D000658:Amoxicillin; D007052:Ibuprofen